Staging amyotrophic lateral sclerosis: A new focus on progression.
Amyotrophic lateral sclerosis
King's College
MiToS
Progression
Staging
Journal
Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
28
06
2018
revised:
04
09
2018
accepted:
07
09
2018
pubmed:
5
1
2019
medline:
14
1
2020
entrez:
5
1
2019
Statut:
ppublish
Résumé
Amyotrophic lateral sclerosis (ALS) is a heterogenous motoneuronal neurodegenerative condition with a panel of phenotypes exhibiting different clinical patterns. Two compounds are currently available for the treatment of ALS but the majority of trials have failed to show a positive effect on prognosis. One of the explanations which could be put forward involves the way efficacy is evaluated: clinicians agree that the ALSFRS-revised scale used in all trials does not fit with highlighting a positive effect. So, the development and validation of new tools allowing a reliable assessment of ALS has become a key issue in clinical research. Over the last three years, two functional scales (the King's College and MiToS staging systems) have been proposed. These scales rely on two different approaches to ALS: an anatomical and prognostic concept, and loss of autonomy. Both scales propose five stages. We will discuss below the contribution of these two scales to clinical evaluation and the questions which remain to be resolved in the future.
Identifiants
pubmed: 30606512
pii: S0035-3787(18)30733-1
doi: 10.1016/j.neurol.2018.09.017
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-282Informations de copyright
Copyright © 2018 Elsevier Masson SAS. All rights reserved.